These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 31983199

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
    Cao D, Deng C, Wang G, Mei X, Xie J, Liu Y, Liu Y, Yang Y, Li S, Liu C.
    Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Analytical and functional similarity of biosimilar ABP 798 with rituximab reference product.
    Seo N, Huang Z, Kuhns S, Sweet H, Cao S, Wikström M, Liu J.
    Biologicals; 2020 Nov; 68():79-91. PubMed ID: 32888776
    [Abstract] [Full Text] [Related]

  • 8. Assessing Analytical and Functional Similarity of Proposed Amgen Biosimilar ABP 980 to Trastuzumab.
    Hutterer KM, Polozova A, Kuhns S, McBride HJ, Cao X, Liu J.
    BioDrugs; 2019 Jun; 33(3):321-333. PubMed ID: 30972630
    [Abstract] [Full Text] [Related]

  • 9. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
    Brown KA, Rajendran S, Dowd J, Wilson DJ.
    Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Part 2: Physicochemical characterization of bevacizumab in 2 mg/mL antibody solutions as used in human i.v. administration: Comparison of originator with a biosimilar candidate.
    Arvinte T, Palais C, Poirier E, Cudd A, Rajendran S, Brokx S, Dowd J.
    J Pharm Biomed Anal; 2019 Nov 30; 176():112802. PubMed ID: 31446298
    [Abstract] [Full Text] [Related]

  • 14. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA, Rule KE, Shiue MHI, Finch GL, Thibault S, Brown PR, Clarke DW, Leach MW.
    Regul Toxicol Pharmacol; 2018 Jun 30; 95():236-243. PubMed ID: 29574193
    [Abstract] [Full Text] [Related]

  • 15. Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment.
    Lee JH, Paek K, Moon JH, Ham S, Song J, Kim S.
    BioDrugs; 2019 Aug 30; 33(4):411-422. PubMed ID: 31190280
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.